Study Title
Myelodysplastic Syndromes (low/int-1 risk) & Transfusional Iron Overload (TELESTO)
Purpose
To assess the efficacy and safety of iron chelation therapy with a single agent compared to placebo in patients with myelodysplastic syndromes (MDS) (low/int-1 risk) and transfusional iron overload.
Eligibility
Male and Female patients at least 18 years of age
Must weigh between 35-135 kg
Low or intermediate risk MDS, confirmed by a bone marrow
Hematologically stable
History of transfusion of 15-75 PRBC units
Anticipated to be transfused with at least 8 units of PRBCs annually
Study Process
Screening Period: up to 30 days
Study visits: every 4 weeks
Eye & Ear exam required during screening
Trial Details
Investigator:
Michael Moore, M.D.
IRB:
Quorum
IRB Number:
Trial Type:
Drug
Sponsor:
Novartis Pharmacy
Contact Information:
Hematology Oncology Associates
(318) 212-8620
http://cancer.wkhs.com